Definitive Healthcare Corp (DH)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $140.38M
Last updated: Nov 17, 2026 at 11:02 AM ET
Definitive Healthcare Corp (DH) Earnings: Report Dates and Results
Definitive Healthcare (DH) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Definitive Healthcare reported EPS of $0.01, in line with the $0.01 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DH has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 33.3% below the $0.06 reported for the quarter ended Dec 31, 2025.
DH Earnings Call
The latest DH earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 22 quarters below that had an estimate, DH beat 14, missed 3 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $54.65M, down 9.0% from $60.05M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.01 | $0.01 | N/A | 0.00% | In line | -85.7% | 6 | 0 up, 2 down | Nov 5, 2026 | $54.65M |
| Jun 30, 2026 | $0.01 | $0.04 | $0.04 - $0.05 | -75.00% | Miss | -50.0% | 7 | 1 up, 0 down | Aug 10, 2026 | $55.20M |
| Mar 31, 2026 | $0.06 | $0.03 | $0.03 - $0.04 | +100.00% | Beat | +20.0% | 11 | 0 up, 7 down | May 7, 2026 | $55.93M |
| Dec 31, 2025 | $0.06 | $0.03 | N/A | +100.00% | Beat | -25.0% | 11 | 0 up, 3 down | Feb 26, 2026 | $61.53M |
| Sep 30, 2025 | $0.07 | $0.06 | $0.05 - $0.06 | +16.67% | Beat | -30.0% | 11 | 1 up, 4 down | Nov 6, 2025 | $60.05M |
| Jun 30, 2025 | $0.02 | $0.02 | N/A | 0.00% | In line | -77.8% | 12 | 3 up, 2 down | Aug 7, 2025 | $60.75M |
| Mar 31, 2025 | $0.05 | $0.02 | $0.02 - $0.04 | +150.00% | Beat | -37.5% | 12 | 0 up, 8 down | May 8, 2025 | $59.19M |
| Dec 31, 2024 | $0.08 | $0.07 | $0.07 - $0.08 | +11.42% | Beat | +14.3% | 13 | 2 up, 3 down | Feb 27, 2025 | $62.29M |
| Sep 30, 2024 | $0.10 | $0.08 | $0.07 - $0.09 | +25.00% | Beat | +11.1% | 12 | 0 up, 0 down | Nov 7, 2024 | $62.70M |
| Jun 30, 2024 | $0.09 | $0.09 | $0.08 - $0.09 | 0.00% | In line | +12.5% | 12 | 1 up, 1 down | Aug 5, 2024 | $63.74M |
| Mar 31, 2024 | $0.08 | $0.08 | $0.08 - $0.09 | 0.00% | In line | +33.3% | 12 | 0 up, 0 down | May 7, 2024 | $63.48M |
| Dec 31, 2023 | $0.07 | $0.08 | $0.06 - $0.09 | -12.50% | Miss | 0.0% | 12 | 0 up, 0 down | Feb 28, 2024 | $65.93M |
| Sep 30, 2023 | $0.09 | $0.06 | $0.05 - $0.08 | +50.00% | Beat | +50.0% | 11 | 0 up, 0 down | Nov 2, 2023 | $65.33M |
| Jun 30, 2023 | $0.08 | $0.06 | $0.04 - $0.08 | +33.33% | Beat | +33.3% | 13 | 3 up, 0 down | Aug 14, 2023 | $60.96M |
| Mar 31, 2023 | $0.06 | $0.04 | $0.04 - $0.05 | +50.00% | Beat | +20.0% | 13 | 0 up, 0 down | May 4, 2023 | $59.20M |
| Dec 31, 2022 | $0.07 | $0.04 | $0.04 - $0.05 | +75.00% | Beat | +75.0% | 12 | 1 up, 0 down | Feb 23, 2023 | $60.60M |
| Sep 30, 2022 | $0.06 | $0.05 | $0.04 - $0.05 | +20.00% | Beat | +500.0% | 10 | 0 up, 0 down | Nov 3, 2022 | $57.38M |
| Jun 30, 2022 | $0.06 | $0.05 | $0.05 - $0.06 | +20.00% | Beat | +50.0% | 10 | 0 up, 0 down | Aug 4, 2022 | $54.55M |
| Mar 31, 2022 | $0.05 | $0.04 | $0.03 - $0.04 | +25.00% | Beat | N/A | 10 | 0 up, 0 down | May 5, 2022 | $50.12M |
| Dec 31, 2021 | $0.04 | $0.04 | $0.04 - $0.05 | 0.00% | In line | N/A | 10 | 0 up, 0 down | Feb 23, 2022 | $46.31M |
| Sep 30, 2021 | $0.01 | $0.02 | $0.01 - $0.02 | -50.00% | Miss | N/A | 8 | N/A | Nov 8, 2021 | $43.08M |
| Jun 30, 2021 | $0.04 | $0.01 | N/A | +300.00% | Beat | N/A | N/A | N/A | Sep 16, 2021 | $39.82M |
| Mar 31, 2021 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2021 | $36.94M |
| Dec 31, 2020 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | $33.66M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.20, down 42.9% from the year before. It was -$0.10 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.20 | -42.9% |
| Dec 31, 2024 | $0.35 | +16.7% |
| Dec 31, 2023 | $0.30 | +25.0% |
| Dec 31, 2022 | $0.24 | N/A |
| Dec 31, 2021 | -$0.01 | N/A |
| Dec 31, 2020 | -$0.10 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,300 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 4,279 | 6 | |
| 2026Q1 | Mar 31, 2026 | 5,670 | 10 | |
| 2025Q4 | Dec 31, 2025 | 6,965 | 9 | |
| 2025Q3 | Sep 30, 2025 | 6,899 | 10 | |
| 2025Q2 | Jun 30, 2025 | 6,523 | 10 | |
| 2025Q1 | Mar 31, 2025 | 6,868 | 10 | |
| 2024Q4 | Dec 31, 2024 | 6,649 | 12 | |
| 2024Q3 | Sep 30, 2024 | 6,426 | 10 |
2026Q2 Earnings Call
Opening remarks
Jonathan Paris Investor Relations Good afternoon, and thank you for joining us to review Definitive Healthcare's financial results. Joining me on today's call are Kevin Coop, our Chief Executive Officer, and Casey Heller, our Chief Financial Officer. Before we begin, I'd like to remind you that today's discussion may include forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements about our market opportunity, future performance, growth in financial guidance, the benefits of our data and health and commercial intelligence solutions, our competitive position, customer behavior, adoption, growth, renewals, and retention, planned investments and operating strategy, value creation for customers and shareholders, and the expected impact of macroeconomic conditions on our business, customers, and the healthcare industry. Forward-looking statements are based on our current expectations and assumptions as of today and are subject to risks and uncertainties that could cause actual results to differ materially. For more information, please refer to the cautionary statement in today's earnings release, as well as the risk factors and other information included in our filings with the SEC, including our most recent Form 10-K and Form 10-Q. You should not place undue reliance on forward-looking statements, and Definitive Healthcare undertakes no obligation to update them except as required by law. During the call, we may also discuss certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures, along with related definitions and limitations, are included in today's earnings release and investor presentation, each of which is available on the Investor Relations section of our website. For any forward-looking non-GAAP measures, the earnings release also explains why quantitative reconciliation is not available without unreasonable efforts and identifies the relevant unavailable items. With that, I'll turn the call over to Kevin.
Kevin Coop Chief Executive Officer Thank you, Jonathan, and thanks to all of you for joining us this afternoon to review Definitive Healthcare's second quarter 2026 financial results. On today's call, I'll provide highlights from our second quarter performance and give an update on our progress against our key strategic priorities for this year. Let me begin by reviewing our financial results for the second quarter, which were in line or exceeded the guidance ranges on both the top and bottom line. Total revenue was $55.2 million, down 9% year-over-year. Adjusted EBITDA was $14.6 million, representing a margin of 26%, which was modestly above the high end of our guidance. We continue to do an effective job of managing expenses while investing in our core growth initiatives. We continue to generate solid cash flow, delivering approximately $50 million of unlevered free cash flow for the trailing 12 months.
Frequently Asked Questions About DH
When is Definitive Healthcare's next earnings date?
Definitive Healthcare's next earnings report is expected for Feb 24, 2027.
Did DH beat earnings estimates last quarter?
Definitive Healthcare reported EPS of $0.01 for the quarter ended Sep 30, 2026, in line with the $0.01 estimate.
What EPS do analysts expect from DH next quarter?
The consensus EPS estimate for Definitive Healthcare for the quarter ending Dec 31, 2026 is $0.04 from 9 analysts, with estimates from $0.03 to $0.06.
How often does DH beat earnings estimates?
Definitive Healthcare beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +37.89%.
DH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts